Fiscal Year 2024 Competitive Cooperative Agreement Solicitation - Drug Court Training and Technical Assistance
ID: 354410Type: Posted
Overview

Buyer

Office of National Drug Control Policy (ONDCP)

Award Range

$6M - $6M

Eligible Applicants

Nonprofits Without 501(c)(3) Status

Funding Category

Law, Justice and Legal Services

Funding Instrument

Cooperative Agreement

Opportunity Category

Discretionary

Cost Sharing or Matching Requirement

Yes

Original Source

https://grants.gov/search-results-detail/354410

Additional Information

https://www.grantsolutions.gov/gs/preaward/previewPublicAnnouncement.do?id=111308
Timeline
    Description

    The Office of National Drug Control Policy (ONDCP) is offering a Fiscal Year 2024 Competitive Cooperative Agreement Solicitation for Drug Court Training and Technical Assistance. This initiative aims to provide training and technical assistance to states, local courts, and government units involved with drug courts, focusing on developing and enhancing alternatives to incarceration for individuals struggling with addiction. The program aligns with the President's priority of improving public safety by addressing various issues such as mental health, vocational training, and substance use through evidence-based rehabilitation programs. The total funding available for this cooperative agreement is $6 million, with a single award anticipated, and applications must be submitted by July 31, 2024. For further inquiries, interested applicants can contact the Grants.gov Customer Support at support@grants.gov or call 1-800-518-4726.

    Point(s) of Contact
    support@grants.gov
    Files
    No associated files provided.
    Similar Opportunities
    Development of Medications to Prevent and Treat Opioid and/or Stimulant Use Disorders and Overdose (UG3/UH3 - Clinical Trial Optional)
    National Institutes of Health
    The National Institutes of Health (NIH), through the National Institute on Drug Abuse (NIDA), has announced a funding opportunity aimed at the development of medications to prevent and treat opioid and stimulant use disorders and overdose. This initiative seeks innovative preclinical and clinical research projects that can lead to FDA-approved therapies, focusing on areas such as prevention of substance use initiation, treatment adherence, and reduction of overdose risks. With a maximum funding amount of $3 million per year over a project period of five years, applicants are encouraged to submit proposals that demonstrate their capability to manage the research effectively, adhering to detailed application instructions. Interested parties can find more information and application details at the NIH grants website, with the application deadline set for September 1, 2025.
    Development of Medications to Prevent and Treat Substance Use Disorders and Overdose (UG3/UH3 - Clinical Trial Optional)
    National Institutes of Health
    The National Institutes of Health (NIH), through the National Institute on Drug Abuse (NIDA), is offering a funding opportunity for the development of medications aimed at preventing and treating substance use disorders (SUDs) and overdose. This initiative is structured into two phases: the UG3 phase focuses on achieving specific milestones within a two-year period, while the UH3 phase extends support for an additional three years for projects that successfully meet the UG3 milestones. Given the urgent need for effective treatments in light of rising overdose deaths, particularly from synthetic opioids and stimulants, this funding opportunity emphasizes innovative research methodologies and the effective application of existing medications. Interested applicants can seek funding of up to $3 million annually for a maximum of five years, with applications due by August 11, 2025. For further inquiries, contact NIH Grants Information at grantsinfo@nih.gov or visit the additional information link at https://grants.nih.gov/grants/guide/pa-files/PAR-25-329.html.
    Drug-Free Communities (DFC) Support Program - NEW (Year 1)
    Centers for Disease Control - NCIPC
    The Centers for Disease Control and Prevention (CDC), through the National Center for Injury Prevention and Control (NCIPC), is offering the Drug-Free Communities (DFC) Support Program grant for Fiscal Year 2025, aimed at supporting community coalitions in preventing and reducing youth substance use. This program seeks to establish and strengthen collaboration among various community sectors and organizations to address substance abuse, with a focus on developing partnerships and utilizing evidence-based strategies. The total estimated funding for this initiative is $62.5 million, with individual grants available up to $125,000 annually, and applications are due by May 5, 2025. Interested applicants can reach out to Christi Jones at dfcnofo@cdc.gov for further information.
    Grand Opportunity in Medications Development for Substance-Use Disorders (U01 Clinical Trial Optional)
    National Institutes of Health
    The National Institutes of Health (NIH), through the National Institute on Drug Abuse (NIDA), is offering a funding opportunity titled "Grand Opportunity in Medications Development for Substance-Use Disorders (U01 Clinical Trial Optional)" aimed at accelerating the development of medications for Substance Use Disorders (SUDs). This initiative encourages research applications for diverse preclinical and clinical projects that can expedite the FDA approval process for new treatments, addressing the significant public health need for effective therapies for conditions such as cocaine, methamphetamine, and cannabis use disorders. The program will provide cooperative agreements for projects lasting up to three years, with annual budgets capped at $5 million, and applications are accepted on a rolling basis with specific due dates for scientific merit review established throughout 2023 and 2024. Interested applicants can reach out to NIH Grants Information at grantsinfo@nih.gov for further inquiries, and additional details can be found at the provided link: https://grants.nih.gov/grants/guide/pa-files/PAR-22-202.html.
    Grand Opportunity in Medications Development for Substance-Use Disorders (U01 Clinical Trial Optional)
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Grand Opportunity in Medications Development for Substance-Use Disorders (U01 Clinical Trial Optional)" aimed at accelerating the development of medications for Substance Use Disorders (SUDs). This initiative encourages research applications that support a diverse range of preclinical and clinical projects, with the goal of advancing medication studies toward FDA approval, emphasizing the importance of innovative approaches to drug misuse and addiction treatment. Eligible applicants include a variety of institutions, such as higher education entities and community organizations, with funding available up to $5 million per year for projects lasting up to three years. Interested parties can find more information and submit inquiries via grantsinfo@nih.gov, with applications due by August 11, 2025.
    Addiction Technology Transfer Centers Cooperative Agreement
    Substance Abuse and Mental Health Services Adminis
    The Substance Abuse and Mental Health Services Administration (SAMHSA) is forecasting a grant opportunity titled "Addiction Technology Transfer Centers Cooperative Agreement" aimed at enhancing the behavioral healthcare and primary healthcare workforce for substance use disorder (SUD) treatment and recovery support services. This initiative seeks to accelerate the adoption of evidence-based practices, improve workforce knowledge and skills, and foster collaborations among diverse stakeholders in the field of substance use and co-occurring health disorders. With an estimated total program funding of $8.6 million and an expected 12 awards, eligible applicants include states, territories, Indian tribes, and nonprofit entities. Interested parties can reach out to Humberto Carvalho at Humberto.Carvalho@samhsa.hhs.gov or (240) 276-2974 for further information, with the synopsis expected to be posted on January 30, 2023.
    Fiscal Year 2025 Behavioral Health National Training and Technical Assistance Partner (NTTAP) Cooperative Agreement
    Health Resources and Services Administration
    The Health Resources and Services Administration (HRSA) is offering a cooperative agreement for the Fiscal Year 2025 to establish a Behavioral Health National Training and Technical Assistance Partner (NTTAP). This initiative aims to provide comprehensive training and technical assistance focused on enhancing behavioral health services in health centers, addressing public health issues, and improving operational effectiveness while reducing health disparities. The program is critical for ensuring that health centers can deliver evidence-informed behavioral health services effectively. The estimated total funding for this opportunity is $2,000,000, with approximately 20 awards expected. Interested applicants can reach out to Marlene Saez-Banks at msaezbanks@hrsa.gov or by phone at 301-443-8806. Key deadlines include the synopsis posting on March 21, 2025, and the closing date for applications on May 20, 2025, with projects expected to start on September 1, 2025.
    Rural Opioid Technical Assistance Regional Centers
    Substance Abuse and Mental Health Services Adminis
    The Substance Abuse and Mental Health Services Administration (SAMHSA) is offering a federal grant opportunity titled "Rural Opioid Technical Assistance Regional Centers." This program aims to establish regional centers of excellence that will provide training and technical assistance to combat opioid and stimulant misuse in rural communities. The initiative is crucial for addressing the growing health crisis related to substance abuse in these areas, with an estimated total program funding of $7,150,000 and the expectation of awarding 11 grants. Interested applicants, including public or nonprofit entities, states, Indian tribes, and health facilities, can reach out to Twyla Adams at (240) 276-1576 or via email at twyla.adams@samhsa.hhs.gov for further information. The opportunity is currently posted, with an estimated synopsis posting date of May 1, 2025.
    First Responders – Comprehensive Addiction and Recovery Act
    Substance Abuse and Mental Health Services Adminis
    The Substance Abuse and Mental Health Services Administration (SAMHSA) is forecasting a grant opportunity titled "First Responders – Comprehensive Addiction and Recovery Act," aimed at supporting first responders and key community members in administering emergency treatments for opioid overdoses. This program is designed to enhance the capacity of eligible entities, including states, local governments, and tribal organizations, to utilize approved drugs or devices for the rapid reversal of opioid overdoses, addressing a critical public health issue. With an estimated total program funding of $5.1 million and an expected 12 awards, interested applicants can reach out to Shannon Hastings at (240) 276-1869 or via email at DTPFRCARA@samhsa.hhs.gov for further information. The synopsis for this opportunity is anticipated to be posted on November 15, 2024, with no cost-sharing or matching requirements.
    Cooperative Agreement to Support Activities Related to Analgesics, Anesthetics, and Addiction (U01) Clinical Trials Allowed
    Food and Drug Administration
    The Food and Drug Administration (FDA) is forecasting a cooperative agreement opportunity titled "Cooperative Agreement to Support Activities Related to Analgesics, Anesthetics, and Addiction (U01)," aimed at advancing research in Anesthesia, Addiction Medicine, and Pain Medicine. Applicants are required to propose comprehensive, evidence-based plans that focus on critical areas such as clinical trial endpoints for chronic pain, outcome measures for stimulant use disorders, and assessments of opioid clinical trials, among others. This initiative is vital for enhancing the understanding and management of analgesics and anesthetics, particularly in vulnerable populations. The FDA anticipates awarding five grants, each with a funding ceiling and floor of $2 million, with applications due for the fiscal year 2025. Interested parties can reach out to Terrin Brown at terrin.brown@fda.hhs.gov or call 240-402-7610 for further information.